Metallodrugs having improved pharmacological properties, and methods of manufacture and use thereof

• US 8,859,492 B2
• Filed: 05/12/2012
• Issued: 10/14/2014
• Est. Priority Date: 05/12/2011
• Status: Expired due to Fees

• Current Assignee: Metallopharm LLC
• Original Assignee: Metallopharm LLC
• Inventors: Cowan, James A., Cowan, Ada S., Palmer, Donna T.
• Primary Examiner(s): Skowronek, Karlheinz R
• Assistant Examiner(s): Lee, Jia-Hai
• Application Number:
  US13/470,299
• Publication Number:
  US 20120289454A1
• Time in Patent Office: 885 Days
• US Class Current: 514/2.3
• CPC Class Codes: A61K 31/424 condensed with heterocyclic ring systems, e.g. clavulanic acid
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/10 Peptides having 12 to 20 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 38/16 Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof enzyme inhibitors A61K38/005
• CPC Class Codes: A61K 47/547 Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: C07F 17/02 of metals of Groups 8, 9 or 10 of the Periodic System
• CPC Class Codes: C07H 21/00 Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
• CPC Class Codes: C07H 23/00 Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12 esters with inorganic acids C07H11/00; metal salts, see parent compounds
• CPC Class Codes: C07K 14/825 Metallothioneins
• CPC Class Codes: C07K 2319/20 containing a tag with affinity for a non-protein ligand
• CPC Class Codes: C07K 2319/70 containing domain for protein-protein interaction
• CPC Class Codes: C07K 5/022 containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids

Abstract

It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.

Claims

1. A compound for catalytically inactivating a biochemical target of interest, comprising:

a ligand moiety which binds to the biochemical target; and

a metal binding moiety,

wherein the ligand moiety is heterologous to the metal binding moiety, wherein the ligand moiety and the metal binding moiety are covalently linked, wherein the compound binds to the biochemical target with an affinity of between about 10⁴ M<sup>−

1</sup> and about 0.7×

10⁷ M<sup>−

1</sup>, and wherein the compound has an off rate (k_off) for its target which is similar to that for the catalytic turnover (k_cat) of the metal binding moiety.

2. The compound according to claim 1, wherein the metal binding moiety comprises a metal bound thereto, wherein said metal is redox-active in the bound state under oxidative conditions to generate one or more reactive oxygen species.

3. The compound according to claim 1, wherein the metal binding moiety has a metal bound thereto, wherein said metal is active as a Lewis acid catalyst in the bound state under hydrolytic conditions.

4. The compound according to claim 1, wherein the metal binding moiety comprises a metal bound thereto, wherein said metal is a cation of a metal selected from the group consisting of an alkaline earth metals, metals which give rise to cations with an incomplete d sub-shell, lanthanide and actinide metals.

5. The compound according to claim 4, wherein the metal which gives rise to cations with an incomplete d-subshell is selected from the group consisting of Cu(II), Cu(III), Ni(II), Ni(III), Zn(II), Fe(II), Fe(III), Co(II), Co(III), Cr(II), and Cr(III), and other second and third row transition metal ions, and non-transition metals such as Al(III).

6. The compound according to claim 1, wherein the ligand moiety comprises a peptide or protein backbone, or pegylated form thereof.

7. The compound according to claim 1, wherein the ligand moiety comprises a carbohydrate backbone, or pegylated form thereof.

8. The compound according to claim 1, wherein the ligand moiety comprises a secondary metabolite, or pegylated form thereof.

9. The compound according to claim 1, wherein the ligand moiety comprises a nucleic acid backbone, or pegylated form thereof.

10. The compound according to claim 1, wherein the ligand moiety comprises a protein nucleic acid backbone, or pegylated form thereof.

11. The compound according to claim 1, wherein the ligand moiety comprises an organic molecular motif selected from the group consisting of an aptamer, a small organic molecule, a peptidomimetic, a dendrimer, an antibiotic, a secondary metabolite, and an antibody (or antibody fragment), or pegylated form thereof.

12. The compound according to claim 1, wherein the metal binding moiety comprises an organic chelating ligand.

13. The compound according to claim 12, wherein said organic chelating ligand coordinates a metal using amine and carboxylate functionalities on the organic chelating ligand.

14. The compound according to claim 12, wherein said organic chelating ligand coordinates a metal using the coordination chemistry of a compound selected from the group consisting of diethylenetriaminepentaacetic acid (DTPA), ethylenediamine tetraacetic acid (EDTA), N,N-bis(carboxymethyl)glycine (NTA), diethylenetriaminepentaacetate (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), Mercaptoacetylglycine (MAG3), 1,4,8,11-Tetraazacyclotetradecane (CYCLAM), 1,4,7,10-tetraazacyclododecane, cyclen, 1,4,7-triazacyclononane (TACN), and hydrazinonicotinamide (HYNIC).

15. The compound according to claim 1, wherein the metal binding moiety comprises a peptide chelating ligand.

16. The compound according to claim 15, wherein said peptide chelating ligand coordinates a metal using terminal amine and/or amino acid sidechains, and/or deprotonated backbone amide, and/or backbone carbonyl functionalities on the peptide chelating ligand.

17. The compound according to claim 15, wherein said peptide chelating ligand is an ATCUN motif.

18. The compound according to claim 1, wherein the biochemical target is selected from the group consisting of a bacterial component, a viral component, a fungal component, a mammalian cellular component, a protozoan component, a serum component, an extracellular matrix component, a cancer cell component, and a pathogen-derived toxin.

19. The compound according to claim 1, wherein the biochemical target is a cellular or serum component selected from the group consisting of a cell receptor, a cytokine, a hormone, an enzyme, and a misfolded or polymeric form of a naturally occurring molecule.

20. The compound according to claim 1, wherein when the composition is bound to the biochemical target, the metal binding moiety is within 20 nm of the biochemical target.

21. A method of improving the efficacy of a current or candidate therapeutic molecule which is a ligand to a biochemical target, comprising:

covalently conjugating said current or candidate therapeutic molecule and which lacks a metal-binding domain, to a metal binding moiety to provide a compound of claim 1, wherein the compound binds to the biochemical target with an affinity of between about 10⁴ M<sup>−

1</sup> and about 0.7×

10⁷ M<sup>−

1</sup>, and wherein the compound has an off rate (k_off) for its target which is similar to that for the catalytic turnover (k_cat) of the metal binding moiety.

22. A method according to claim 21, wherein the metal binding moiety comprises a metal bound thereto, wherein said metal is redox-active in the bound state under oxidative conditions to generate one or more reactive oxygen species.

23. A method according to claim 21, wherein the metal binding moiety has a metal bound thereto, wherein said metal is active as a Lewis acid catalyst in the bound state under hydrolytic conditions.

24. A method for catalytically inactivating a biochemical target of interest, comprising:

contacting the biochemical target of interest with the compound according to claim 1 under conditions wherein the composition binds to, and generates reactive oxygen species proximate to, the biochemical target, wherein the concentration of reactive oxygen species generated conformationally and/or functionally alters the biochemical target, thereby inactivating the biochemical target.

25. The method according to claim 24, wherein the metal binding moiety has a metal bound thereto, wherein said metal is active as a Lewis acid catalyst in the bound state under hydrolytic conditions.

26. The method according to claim 24, wherein the metal binding moiety comprises a metal bound thereto, wherein said metal is a cation of a metal selected from the group consisting of an alkaline earth metals, metals which give rise to cations with an incomplete d sub-shell, and actinide metals.

27. A method according to claim 26, wherein the transition metal is selected from the group consisting of Cu(II), Cu(III), Ni(II), Ni(III), Zn(II), Fe(II), Fe(III), Co(II), Co(III), Cr(II), and Cr(III), and other second and third row transition metal ions, and non-transition metals such as Al(III).

28. A method according to claim 21, wherein the ligand moiety comprises a peptide or protein backbone, or pegylated form thereof.

29. A method according to claim 21, wherein the ligand moiety comprises a carbohydrate backbone, or pegylated form thereof.

30. A method according to claim 21, wherein the ligand moiety comprises a secondary metabolite, or pegylated form thereof.

31. A method according to claim 21, wherein the ligand moiety comprises a nucleic acid backbone, or pegylated form thereof.

32. A method according to claim 21, wherein the ligand moiety comprises a protein nucleic acid backbone, or pegylated form thereof.

33. A method according to claim 21, wherein the ligand moiety comprises an organic molecular motif selected from the group consisting of an aptamer, a small organic molecule, a peptidomimetic, a dendrimer, an antibiotic, a secondary metabolite, and an antibody, or pegylated form thereof.

34. A method according to claim 21, wherein the metal binding moiety comprises an organic chelating ligand.

35. A method according to claim 34, wherein said organic chelating ligand coordinates a metal using amine and carboxylate functionalities on the organic chelating ligand.

36. A method according to claim 34, wherein said organic chelating ligand coordinates a metal using the coordination chemistry of a compound selected from the group consisting of diethylenetriaminepentaacetic acid (DTPA), ethylenediamine tetraacetic acid (EDTA), N,N-bis(carboxymethyl)glycine (NTA), diethylenetriaminepentaacetate (DTPA), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), Mercaptoacetylglycine (MAG3), 1,4,8,11-Tetraazacyclotetradecane (CYCLAM), 1,4,7,10-tetraazacyclododecane, cyclen, 1,4,7-triazacyclononane (TACN), and hydrazinonicotinamide (HYNIC).

37. A method according to claim 21, wherein the metal binding moiety comprises a peptide chelating ligand.

38. A method according to claim 37, wherein said peptide chelating ligand coordinates a metal using terminal amine and/or amino acid sidechains, and/or deprotonated backbone amide, and/or backbone carbonyl functionalities on the peptide chelating ligand.

39. A method according to claim 37, wherein said peptide chelating ligand is an ATCUN motif.

40. A method according to claim 21, wherein the biochemical target is selected from the group consisting of a bacterial component, a viral component, a fungal component, a human cellular component, a protozoan component, a serum component, an extracellular matrix component, a cancer cell component, and a pathogen-derived toxin.

41. A method according to claim 21, wherein the biochemical target is a cellular or serum component selected from the group consisting of a cell receptor, a cytokine, a hormone, an enzyme, and a misfolded or polymeric form of a naturally occurring molecule.

42. A method according to claim 21, wherein when the composition is bound to the biochemical target, the metal binding moiety is within 20 nm, and preferably within 20 Å

, of the biochemical target.

43. A method for therapeutically inactivating a biochemical target, comprising:

administering to a subject in need thereof the compound according to claim 1 under conditions wherein the composition binds to, and generates reactive oxygen species proximate to, the biochemical target, wherein the concentration of reactive oxygen species generated conformationally and/or functionally alters the biochemical target to therapeutic effect.

44. A method according to claim 43, administering to a subject in need thereof the compound according to claim 1 under conditions wherein the compound binds to the biochemical target, and is active as a Lewis acid catalyst in the bound state under hydrolytic conditions.